trial · primary record
Resiniferatoxin
Intractable Pain
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2026-12-01 |
| Primary endpoint | To investigate the safety and efficacy of RTX administered intrathecally in subjects with severe refractory pain associated with advanced cancer along with ED100, the MTD, or the maximum dose administered, whichever is achieved first during dose... |
| Registry ID | NCT02522611 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:46.264Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02522611
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.